111490-36-9|Zeniplatin|Platinum, (2,2-bis(aminomethyl)-1,3-propanediol-N,N')(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)-|-范德生物科技公司

Zeniplatin

NMR下载 COA and HPLC MSDS下载
names：
Platinum, (2,2-bis(aminomethyl)-1,3-propanediol-N,N')(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)-
CAS号：
111490-36-9
MDL Number：
MF(分子式)： C11H18N2O6Pt MW(分子量)： 469.357
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Platinum, (2,2-bis(aminomethyl)-1,3-propanediol-N,N')(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)-
英文别名	Zeniplatin; Zeniplatinum.
CAS号	111490-36-9
Inchi	InChI=1S/C6H8O4.C5H12N2O2.Pt/c7-4(8)6(5(9)10)2-1-3-6;6-1-5(2-7,3-8)4-9;/h1-3H2,(H,7,8)(H,9,10);6-9H,1-4H2;/q;-2;+4/p-2
InchiKey	QPWBZVAOCWJTFK-UHFFFAOYSA-L
分子式 Formula	C11H18N2O6Pt
分子量 Molecular Weight	469.357
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Zeniplatin(CAS:111490-36-9):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Zeniplatin is a biochemical.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Aamdal S, Bruntsch U, Kerger J, Verweij J, ten Bokkel Huinink W, Wanders J, Rastogi R, Franklin HR, Kaye SB. Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity. Cancer Chemother Pharmacol. 1997;40(5):439-43. PubMed PMID: 9272122.

[2]Olver I, Green M, Peters W, Zimet A, Toner G, Bishop J, Ketelbey W, Rastogi R, Birkhofer M. A phase II trial of zeniplatin in metastatic melanoma. Am J Clin Oncol. 1995 Feb;18(1):56-8. PubMed PMID: 7847260.

[3] DeMarco LC, Budman DR, Lathia C, Amorusi P, Birkhofer M, Lichtman S, Weiselberg L, Vinciguerra V, Lovecchio J, Gal D, et al. Pharmacokinetic evaluation of zeniplatin in humans. Cancer Chemother Pharmacol. 1995;36(1):35-40. PubMed PMID: 7720173.

[4] Sorensen JB. Treatment of non-small cell lung cancer: new cytostatic agents. Lung Cancer. 1993 Dec;10(3-4):173-87. Review. PubMed PMID: 8075965.

[5] Markman M, DeMarco LC, Birkhofer M, Budman D, Hakes T, Reichman B, Rubin S, Jones W, Barakat R, Curtin J, et al. Phase II trial of zeniplatin (CL 286,558), a new patinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapy. J Cancer Res Clin Oncol. 1993;119(4):234-6. PubMed PMID: 8423199.

6: Willemse PH, Gietema JA, Mulder NH, de Vries EG, Meijer S, Bouma J, Birkhofer M, Rastogi RB, Sleijfer DT. Zeniplatin in patients with advanced ovarian cancer, a phase II study with a third generation platinum complex. Eur J Cancer. 1993;29A(3):359-62. PubMed PMID: 8398335.7: Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, de Vries EG. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res. 1992 Dec 15;52(24):6885-9. PubMed PMID: 1458477.8: Christian MC. The current status of new platinum analogs. Semin Oncol. 1992 Dec;19(6):720-33. Review. PubMed PMID: 1462169.9: Aamdal S. Can ondansetron hydrochloride (Zofran) enhance the nephrotoxic potential of other drugs? Ann Oncol. 1992 Nov;3(9):774. PubMed PMID: 1450070.10: Dodion PF, de Valeriola D, Crespeigne N, Kantrowitz JD, Piccart M, Wery F, Kerger J, Egorin MJ, Forrest A, Bachur NR, et al. Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex. Ann Oncol. 1991 Sep;2(8):589-96. PubMed PMID: 1793726.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开